Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Biliary Tract Neoplasms

In brief

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).

Key facts

Study ID: NCT03875235
Run by: AstraZeneca
People needed: 810
Starts: 2019-04-16
Expected to finish: 2027-05-16
Last updated by the study team: 2026-05-26

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

Where it is running

Research Site — Orange, California, United States
Research Site — Washington D.C., District of Columbia, United States
Research Site — Fort Myers, Florida, United States
Research Site — St. Petersburg, Florida, United States
Research Site — Westwood, Kansas, United States
Research Site — Louisville, Kentucky, United States
Research Site — Burlington, Massachusetts, United States
Research Site — St Louis, Missouri, United States
Research Site — Chapel Hill, North Carolina, United States
Research Site — Portland, Oregon, United States
Research Site — Philadelphia, Pennsylvania, United States
Research Site — Chattanooga, Tennessee, United States
Research Site — Nashville, Tennessee, United States
Research Site — Seattle, Washington, United States
Research Site — Buenos Aires, Argentina
Research Site — CABA, Argentina
Research Site — CABA, Argentina
Research Site — Ciudad de Buenos Aires, Argentina
Research Site — Ciudad de Buenos Aires, Argentina
Research Site — Rosario, Argentina
Research Site — San Salvador de Jujuy, Argentina
Research Site — Burgas, Bulgaria
Research Site — Sofia, Bulgaria
Research Site — Sofia, Bulgaria
Research Site — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.